Condition
Pancreatic Intraductal Papillary-Mucinous Neoplasm
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 64/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results67% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 3 (1)
Trial Status
Completed2
Terminated1
Unknown1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT01013649Phase 3Completed
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery
NCT02070705Not ApplicableTerminated
DCE MRI in Patients With Pancreatic Cancer
NCT01643460Not ApplicableCompleted
Endoscopic Ultrasound (EUS)-Guided Ablation of Pancreatic Cysts
NCT03884179Unknown
Diagnosis of PCL With EUS-FNA and Cross-sectional Imaging - A Report of Accuracy
Showing all 4 trials